ETCapital
ET Capital is an early-stage venture capital firm located in Cambridge, United Kingdom, a prominent hub for technology. Founded in 1992, the firm specializes in investing in growth-stage companies across various sectors, including life sciences, healthcare, materials, and technology. Since its inception, ET Capital has supported numerous entrepreneurs in their efforts to develop successful businesses, resulting in three companies going public and eight achieving profitable exits. The firm focuses on nurturing innovative ventures, contributing to the dynamic ecosystem of the UK's technology landscape.
Materials Nexus
Seed Round in 2023
Materials Nexus is a deep-tech company focused on advancing sustainable materials through an innovative material modeling platform. By automating quantum calculations, the company enhances the accuracy of material research at scale, thereby facilitating the development of green materials that contribute to net-zero emissions. Utilizing insights from quantum mechanics and artificial intelligence, Materials Nexus aims to reduce greenhouse gas emissions in the materials sector, providing clients with access to sustainable building solutions. Through its efforts, the company seeks to accelerate the transition to environmentally friendly materials and support the global shift toward sustainability.
Phico Therapeutics
Venture Round in 2009
Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.
Phico Therapeutics
Venture Round in 2006
Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.
Bango
Venture Round in 2002
Bango plc is a technology company based in Cambridge, United Kingdom, specializing in mobile payment solutions for content and services. Founded in 1999, Bango develops, markets, and sells technology that facilitates the marketing and sale of products directly to mobile phone users. The company operates through two segments: End User Activity and Data Activity. Its key offering, the Bango Payment Platform, enables app stores and content providers to establish billing connections with mobile operators globally, thereby streamlining the payment process for users. In addition to this platform, Bango offers products such as Bango Marketplace, which aids developers in targeting specific customer audiences, and Bango Resale, which helps merchants acquire and retain customers through global partnerships. The company also features Audiens, a mobile data exchange platform, and partners with leading global stores and payment providers to enhance user engagement and revenue generation. Bango's operations extend across the United Kingdom, European Union, the United States, Canada, and internationally.
Cyan Technology
Series A in 2000
Cyan Technology Ltd develops and markets ultra low power RISC microcontroller with configurable peripherals.
Plastic Logic
Seed Round in 2000
Plastic Logic Ltd specializes in the development and manufacturing of plastic electronics, particularly flexible displays. The company produces both color and monochrome electrophoretic displays, which are utilized in a variety of applications including smartphones, e-readers, tablets, signage, wristwatches, and automotive displays. With a focus on lightweight, shatterproof, and energy-efficient technology, Plastic Logic's products offer significant advantages over traditional screens. The company's manufacturing capabilities are centered in Dresden, Germany, where it operates a pioneering facility dedicated to organic electronics. It serves a diverse clientele, including OEMs, system integrators, and device manufacturers in multiple countries, including the United Kingdom, Germany, and Russia. Additionally, Plastic Logic collaborates with third-party companies through an open pilot line, providing expertise in the industrialization of flexible electronics. Founded in 2000 and based in Cambridge, Plastic Logic continues to innovate in the field of flexible display technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.